The 4 most recent market catalysts affecting $LABT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 21, 2026
Corporate Catalyst
Bullish
Impact 65
Lakewood-Amedex Biotherapeutics Presents Research Highlighting Antimicrobial Profile Of Nu-3, Lead Clinical Candidate, At IDWeek 2026; Topline Data From Trial Expected In Q1 2027
Lakewood-Amedex Biotherapeutics (LABT) announced the presentation of research on its lead clinical candidate, Nu-3, at IDWeek 2026. The research highlights Nu-3's rapid and broad-s…
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 75
LABT stock has given up its prior gain. Lakewood-Amedex Biotherapeutics shares were trading higher after the company announced preclinical data in UTI and pulmonary infection indications in animal models treated with Bisphosphocin compounds.
The headline indicates a significant corporate catalyst for Lakewood-Amedex Biotherapeutics (LABT). Positive preclinical data in animal models for Bisphosphocin compounds in UTI an…
Sep 28, 2026
Corporate Catalyst
Bullish
Impact 65
Lakewood-Amedex Biotherapeutics Announces Minimum Inhibitory Concentration Data From Recent Clinical Isolates Of Nu-3 Demonstrates Consistent Activity Against All Organisms
Lakewood-Amedex Biotherapeutics (LABT) reported positive MIC data for its antimicrobial candidate, Nu-3, showing consistent activity against various clinical isolates and a strong …
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 65
Lakewood-Amedex Biotherapeutics Announces Resistance Data For Nu-3 In Alignment With Presidential Advisory Council On Combating Antibiotic Resistant Bacteria
Lakewood-Amedex Biotherapeutics (LABT) announced that resistance data for its drug candidate, Nu-3, aligns with the Presidential Advisory Council on Combating Antibiotic Resistant …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.